Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus INDOMETHACIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus INDOMETHACIN SODIUM.
ANAPROX DS vs INDOMETHACIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, antipyretic, and analgesic effects.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
Intravenous: 0.5 mg/kg every 12 hours or 0.25 mg/kg every 6 hours for patent ductus arteriosus closure in neonates. Oral/immediate-release: 25-50 mg two to three times daily. Extended-release: 75 mg once daily or 75 mg twice daily. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life: 4.5 hours (range 2.6–11.2 hours); half-life may be prolonged in neonates, elderly, and renal impairment
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal (60% as unchanged drug and metabolites, predominantly glucuronide conjugate); fecal (33%, primarily via biliary secretion); <5% unchanged in urine
Category C
Category D/X
NSAID
NSAID